Sequana Medical Announces 2019 Full Year Results and 2020 Outlook

NEXT STORY
Novartis receives approval from Japanese Ministry of Health, Labour and Welfare for Zolgensma® the only gene therapy for patients with spinal muscular atrophy (SMA)
PREV STORY
The North America genetic testing services market is expected to reach US$ 7,406.0 Mn in 2027 from US$ 3,044.4 Mn in 2019
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

RedHill Biopharma Announces Preferred Position for Talicia® on Express Scripts National Preferred Formulary Effective March 13, 2020

author_avatar
NASDAQ Market News

The healthcare-associated infectious disease diagnostics market is expected to grow at a CAGR of over 8% during the period 2018–2024

author_avatar
NASDAQ Market News

FIT Biotech Oy: Positive results from gene therapy collaboration with Avacta

FIT Biotech Oy  Company release 22.5.2018 at 9.30 EET Positive results from gene therapy ...

author_avatar
NASDAQ Market News